Spruce Street Capital LP holds a focused book of 30 stocks worth $509.7M as of Q2 2026 (disclosed Aug 13, 2026, a ~44-day 13F lag). This quarter they opened Inflarx NV and trimmed Dianthus Therapeutics Inc. Their largest long position is Kiniksa Pharmaceuticals Inte at 12% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Spruce Street Capital LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 36 / 30 | $867.1M |
| MORGAN STANLEY | 36 / 30 | $695.3M |
| BlackRock, Inc. | 34 / 30 | $3.5B |
| BNP PARIBAS FINANCIAL MARKETS | 34 / 30 | $111.9M |
| GEODE CAPITAL MANAGEMENT, LLC | 33 / 30 | $1.2B |
| BARCLAYS PLC | 33 / 30 | $77.2M |
| GOLDMAN SACHS GROUP INC | 32 / 30 | $529.7M |
| BANK OF AMERICA CORP /DE/ | 32 / 30 | $441.1M |
Ranked by how many of Spruce Street Capital LP's top 30 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $58.7M | 918.1K | 11.5% | ▲+21% Added · +157K sh | |
| 2 | Relay Therapeutics Inc COM | $55.8M | 2.98M | 11.0% | —Held | |
| 3 | LB Pharmaceuticals Inc COM SHS | $44.7M | 1.38M | 8.8% | —Held | |
| 4 | Relmada Therapeutics Inc COM | $44.2M | 6.39M | 8.7% | ▲+2.1% Added · +129K sh | |
| 5 | Alto Neuroscience Inc COM SHS | $35.7M | 1.35M | 7.0% | ▲+2.1% Added · +28K sh | |
| 6 | Dianthus Therapeutics Inc COM | $34.6M | 354.8K | 6.8% | ▼−4.9% Reduced · −18K sh | |
| 7 | Alkermes PLC SHS | $28.5M | 543.9K | 5.6% | ▲+71% Added · +226K sh | |
| 8 | Savara Inc COM | $21.3M | 3.45M | 4.2% | ▲+2.0% Added · +69K sh | |
| 9 | Vaxcyte Inc COM | $17.8M | 306.0K | 3.5% | ▲+25% Added · +60K sh | |
| 10 | Enliven Therapeutics Inc COM | $16.7M | 329.0K | 3.3% | —Held | |
| 11 | Enanta Pharmaceuticals Inc COM | $15.9M | 1.09M | 3.1% | ▲+17% Added · +156K sh | |
| 12 | Perspective Therapeutics Inc COM NEW | $12.6M | 3.69M | 2.5% | ▲+41% Added · +1.1M sh | |
| 13 | Inflarx NV COM | $12.0M | 5.35M | 2.4% | ▲New New position | |
| 14 | Surrozen Inc COM NEW | $11.2M | 432.0K | 2.2% | —Held | |
| 15 | Alumis Inc COM | $11.0M | 392.6K | 2.2% | —Held | |
| 16 | Century Therapeutics Inc COM | $9.9M | 4.06M | 2.0% | —Held | |
| 17 | Minerva Neurosciences Inc COM NEW | $9.2M | 1.66M | 1.8% | —Held | |
| 18 | SAB Biotherapeutics Inc COM NEW | $8.6M | 2.20M | 1.7% | —Held | |
| 19 | An2 Therapeutics Inc COM | $8.0M | 1.66M | 1.6% | —Held | |
| 20 | Erasca Inc COM | $7.7M | 422.5K | 1.5% | —Held | |
| 21 | Inhibikase Therapeutics Inc COM NEW | $7.3M | 3.58M | 1.4% | —Held | |
| 22 | Research Alliance Corp III ORD SHS CL A | $5.3M | 500.0K | 1.0% | ▲New New position | |
| 23 | Helix Acquisition Corp III USD CL A ORD SHS | $5.3M | 500.0K | 1.0% | —Held | |
| 24 | Zai Lab Ltd ADR | $5.3M | 279.1K | 1.0% | ▲New New position | |
| 25 | Achieve Life Science Inc COM | $4.8M | 736.6K | 0.9% | ▲New New position | |
| 26 | Lexeo Therapeutics Inc COM | $4.3M | 928.6K | 0.8% | —Held | |
| 27 | Alector Inc COM | $4.2M | 2.10M | 0.8% | —Held | |
| 28 | Leonabio Inc COM | $3.6M | 393.7K | 0.7% | —Held | |
| 29 | Corvus Pharmaceuticals Inc COM | $3.5M | 231.6K | 0.7% | —Held | |
| 30 | Jatt II Acquisition Corp ORD SHS | $1.8M | 160.0K | 0.4% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2050194/holdings"
Use Arkolith to show Spruce Street Capital LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.